Allergen-specific Immunoglobulin G4 recognizing Dactylis glomerata grass pollen allergens (D. glomerata-specific IgG4)

Allergen-specific Immunoglobulin G4 (IgG4) recognizing Dactylis glomerata (Orchard grass) pollen allergens is a key protective antibody produced by the immune system, particularly during allergen immunotherapy (AIT) [Shamji MH, et al., J Allergy Clin Immunol, 2017]. Its primary biological function is to act as a 'blocking antibody' that competes with allergen-specific IgE for binding sites on pollen allergens such as Dac g 1 and Dac g 5 [Aalberse RC, et al., Clin Exp Allergy, 2009]. By sequestering these allergens, IgG4 prevents the cross-linking of IgE on the surface of mast cells and basophils, thereby inhibiting the release of inflammatory mediators like histamine [James LK, et al., Curr Allergy Asthma Rep, 2016]. Furthermore, IgG4 can facilitate the recruitment of inhibitory signaling pathways through the FcγRIIb receptor, promoting immune tolerance [Shamji MH, et al., 2017]. In the context of allergic disease, elevated levels of D. glomerata-specific IgG4 are associated with reduced symptoms of allergic rhinitis and asthma during grass pollen season [Wachholz PA, et al., J Allergy Clin Immunol, 2003]. Therapeutic strategies, such as subcutaneous or sublingual immunotherapy (e.g., Oralair), specifically aim to induce the production of this antibody to provide long-term desensitization [FDA, Oralair Prescribing Information]. Consequently, it serves as a critical biomarker for monitoring the efficacy and immunological shift from a Th2-driven allergic response to a more regulated immune state.

Other names

Orchard grass-specific IgG4Cocksfoot-specific IgG4Anti-Dac g IgG4Dactylis glomerata-specific immunoglobulin G4Blocking antibody IgG4 (Dactylis glomerata)

Induction of allergen-specific IgG4 antibodies that competitively inhibit IgE-allergen binding and activate inhibitory FcγRIIb signaling [Shamji MH, et al., 2017; Aalberse RC, et al., 2009].